Amlan Bishal, Sounik Banerjee, Tamal Maity, Rupajit Bhattacharjee, Satya Prasanna Das. Toxicology: A Current Concept & Trends, ASIO Journal of Pharmaceutical & Herbal Medicines Research (ASIO-JPHMR), 2016: 2(1), 09-20.
ARTICLE TYPE: Review
dids/doi No.: 12.2015-77737978
dids link: http://dids.info/didslink/02.2016-22938794/
Toxicology may be defined as “the study of the detection, occurrence, properties, effects, and regulation of toxic substances,” although more expressive, do not resolve the difficulties. Toxicity itself cannot often, if ever, be defined as a single molecular event but is, rather, a cascade of events starting with exposure, proceeding through distribution and metabolism, and ending with interaction with cellular macromolecules (usually DNA or protein) and the expression of a toxic end point. Persistent pesticides applied directly to the soil have the possible to move from the soil into the water and thus enter the food chain from both soil and water. At the same time fertilizers leach out of the soil or runoff during rain events and flow into the natural water systems. Due to overlapping of mechanisms as well as use and chemical classes of toxicants, clear division into subjects of equal extent or significance is not possible. Exposure of humans and other organisms to toxicants may result from many activities: intentional ingestion, occupational exposure, environmental exposure, as well as accidental and intentional (suicidal or homicidal) poisoning. The toxicity of exacting compound may vary with the gateway of access into the body, whether through the alimentary canal, the lungs, or the skin.
Key Words: Toxicology, Measurement, History, Carcinogens.
- Eriksson UJ, Cederberg J, Wentzel P. Congenital malformations in off spring of diabetic mothers- animal and human studies. Rev Endocrinol Metabol Dis, 2003; 4: 79–93.
- Wilson RD. Principles of human teratology: drug, chemical, and infectious exposure. SOGC Clinical Practice Guidelines, No. 199, November 2007. J Obstet Gynaecol Can, 2007; 29: 911-917.
- Woolf SH, Battista RN. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. Can Med Assoc J, 2003; 169(3): 207–8.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2005; 28:S37–42.
- Zaw W, Stone DG. Caudal regression syndrome in twin pregnancy with type II diabetes. J Perinatol, 2002; 2:171–4.
- Smoak IW. Hypoglycemia and embryonic heart development. Front Biosci, 2002; 7:d307–18.
- Savion S, Gidon-Dabush S, Fein A, Torchinsky A, Toder V. Diabetes teratogenicity is accompanied by alterations in macrophages and T cell subpopulations in the uterus and lymphoid organs. Int Immunopharmacol, 2004; 4:1319–27.
- Lian Q, Thameem Dheen S, Liao D, Sam Wah Tay S. Enhanced inflammatory response in neural tubes of embryos derived from diabetic mice exposed to a teratogen. J Neuroscience Res, 2004; 75:554–64.
- Punareewattana K, Sharova LV, Li W, Ward DL, Holladay SD. Reduced birth defects caused by maternal immune stimulation may involve increased expression of growth promoting genes and cytokine GM-CSF in the spleen of diabetic ICR mice. Int Immunopharmacol, 2003; 3:1639–55.
- Meltzer SJ, Ryan EA, Feig DS, Thompson D, Snyder J. Preconception care for women with diabetes. Canadian Diabetes Association, Clinical Practice Guidelines, 2003.
- Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or pre-existing diabetes. Early Human Develop, 2001; 61:85–95.
- Sheffield JS, Butler-Koster, Casey BM, McIntire DD, Leveno KJ. Maternal diabetes and infant malformations. Obstet Gynecol, 2002; 100:925–30.
- Sharpe PB, Chan A, Haan EA, Hiller JE. Maternal diabetes and congenital anomalies in South Australia 1986–2000: a population-based cohort study. Birth Defects Res, 2005; 73:605–11.
- Martinez-Frias ML, Rodriguez-Pinilla ES, Bermejo E, Prieto. Epidemiological evidence that maternal diabetes does not appear to increase the risk for Down syndrome. Am J Med Genetics, 2002; 112:335–7.
- Evers IM, de Valk HW, Visser GHA. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ, 2004; 328:915–9.
- Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Moeller M, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care, 1004; 27:2819–23.
- Dunne FP, Brydon PA, Proffitt M, Sith T, Gee H, Holder RL. Fetal and maternal outcomes in Indo-Asian compared to Caucasian women with diabetes in pregnancy. Q J Med, 2000; 93 :813–18.
- Langer O, Conway DL. Level of glycemia and perinatal outcome in pregestational diabetes. J Mat Fet Med, 2000; 9:35–41.
- American Diabetes Association. Gestational diabetes mellitus. Diabetes Care, 2000; 23:S77–9.
- Temple R, Aldridge V, Greenwood R, Heyburn P, Sampson M, Stanley K. Association between outcomes of pregnancy in type 1 diabetes: population based study. BMJ, 2002; 325:1275–6.
- Schaefer-Graf UM, Buchanan TA, Xiang A, Songster G, Montoro M, Kjos SL. Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by Type 2 and gestational diabetes. Am J Obstet Gynecol, 2000; 182:313–20.
- Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type 1 diabetes mellitus. Diabetologia, 2000; 43:79–82.
- Farrell T, Neale L, Cundy T. Congenital anomalies in the offspring of women with type 1, type 2 and gestational diabetes. Diabet Med, 2002; 19:322–6.
- McElduff A. Cheung NW, McIntyre HD, Lagstom JA, Oats JJN, Ross GP, et al. The Australasian Diabetes in Pregnancy Society consensus guidelines for the management of type 1 and type 2 diabetes in relation to pregnancy. MJA, 2005; 183:373–7.
- Versiani BR, Gilbert-Barness E, Giuliani LR, Peres LC, Pina-Neto JM. Caudal dysplasia sequence: severe phenotype presenting in offspring of patients with gestational and pregestational diabetes. Clin Dysmorphol, 2004; 13:1–5.
- American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2005; 25:S82–4.
- Berger H, Crane J, Farine D, Armson BA, de la Ronde S, Keenan-Lindsay L, Leduc L, et al. Screening for gestational diabetes. J Obstet Gynaecol Can, 2002; 24:894–903.
- Merlob P, Levitt O, Stahl B. Oral antihyperglycemic agents during pregnancy and lactation: a review. Paediatr Drugs, 2002; 4:755–60.
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes and obesity-related health risk factors, 2001.JAMA, 2003;298:76–9.
- Dolci M, Mori M, Baccetti F. Use of glargine insulin before and during pregnancy in a woman with type I diabetes and Addison’s disease. Diabetes Care, 2005; 28:2084–5.
- Di Cianni G, Volpe L, Lencioni C, Chatzianagnostou K, Cuccuru I, Ghio A, et al. Use of insulin glargine during the first weeks of pregnancy in five type I diabetic women. Diabetes Care, 2005; 28:982–3.
- Woolderink JM, van Loon AJ, Storms F, de Heide L, Hoogenberg K. Use of insulin glargine during pregnancy in seven type I diabetic women. Diabetes Care, 2005; 28:2594–5.
- Watkins ML, Rasmussen SA, Honein MA, Botto LD, Moore CA. Maternal obesity and risk of birth defects. Pediatr, 2003; 111; 1152–8.
- Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol, 2002; 21:181–9.
- Cedergren ML, Kallen BAJ. Maternal obesity and infant heart defects. Obes Res, 2003; 11:1065–71.
- Anderson JL, Waller DK, Canfield MA, Shaw GM, Watkins ML, Werler MM. Maternal obesity, gestational diabetes, and central nervous system birth defects. Epidemiol, 2005; 16:87–92.
- Moore LL, Singer MR, Bradlee ML, Rothman KJ, Milunsky A. A prospective study of the risk of congenital defects associated with maternal obesity and diabetes mellitus. Epidemiol, 2000; 11:689–94.
- Martinez-Frias ML, Frias JP, Bermejo E, Rodriguez-Pinilla E, Prieto L, Frias JL. Pre-gestational maternal body mass index predicts an increased risk of congenital malformations in infants of mothers with gestational diabetes. Diabet Med, 2005; 22:775–81.
- Huttly W, Rudnicka A, Wald NJ. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn, 2004; 24; 804–7.
- American Diabetes Association. Preconception care of women with diabetes. Diabetes Care, 2004; 27:S76–8.
- Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. Q J Med, 2001; 94:435–44.
- McElvy SS, Miodovnik M, Rosenn B, Khoury JC, Siddiqi T, Dignan PSJ, et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med, 2000; 9:14–20.
- Diabetes and Pregnancy Group, France. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care, 2003; 26:2990–3.
- Hadden DR, Alexander A, McCance DR, Traub AI. Northern Ireland Diabetes Group and the Ulster Obstetrical Society. Obstetric and diabetic care for pregnancy in diabetic women: 10 years outcome analysis, 1985–1995. Diabetic Med, 2001; 18:546–53.
- Wilson RD, Davies G, Desiliets V, Reid GJ, Summers A, Wyatt P, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can, 2003; 138:959–65.